Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 10/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 5/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14184766 | 1.00 | MTOR (0.46) | MTORPIK3CAPDCD1CD274PDPK1 | |
| SCHEMBL4928603 | 0.87 | HSD17B10 (0.41) | — | |
| SCHEMBL4919626 | 0.81 | MAP3K12 (0.39) | GRIA1 | |
| SCHEMBL4931945 | 0.79 | PIK3CA (0.46) | MTORPIK3CA | |
| SCHEMBL4923945 | 0.78 | SYK (0.44) | — | |
| SCHEMBL12903213 | 0.74 | MTOR (0.53) | MTORPIK3CAPDCD1CD274PDPK1 | |
| SCHEMBL908123 | 0.74 | MTOR (0.53) | MTORPIK3CAPDCD1CD274PDPK1 | |
| SCHEMBL908122 | 0.74 | MTOR (0.53) | MTORPIK3CAPDCD1CD274PDPK1 | |
| SCHEMBL4920729 | 0.73 | HSD17B10 (0.47) | — | |
| SCHEMBL3877308 | 0.71 | MTOR (0.48) | MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | MTOR 2002/4885PIK3CA 756/4885PDCD1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.